Form 4: Fennec Pharmaceuticals Director Rosty Raykov Reports Share Release
SEC Form 4 Filing
Director Rosty Raykov reports the release of restricted shares of Fennec Pharmaceuticals.
Summary
- On April 30, 2025, Rosty Raykov, a director of Fennec Pharmaceuticals Inc., reported a transaction involving common shares.
- The transaction involved the release of restrictions on 2,431 shares, resulting in Raykov beneficially owning 63,587 common shares following the transaction.
Sentiment
Score: 5
Explanation: This is a neutral report of a routine transaction. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to insider transactions and provides transparency to the market regarding the holdings of company directors.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider holdings.
Key Dates
| Date | Description |
|---|---|
| 03/31/2023 | Date of original share award. |
| 04/30/2025 | Date of transaction (release of restriction from shares). |
| 05/01/2025 | Date of signature on the Form 4 filing. |
Keywords
Form 4, Beneficial Ownership, Director, Fennec Pharmaceuticals, FENC, Raykov, Share Release
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.